GARY W. PACE - 28 Feb 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Director
Signature
/s/ Kristen Williams, Attorney-in-Fact
Issuer symbol
PCRX
Transactions as of
28 Feb 2022
Net transactions value
-$1,675,550
Form type
4
Filing time
01 Mar 2022, 17:03:34 UTC
Previous filing
22 Sep 2021
Next filing
07 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $108,073 +9,807 +7.6% $11.02 139,337 28 Feb 2022 Direct
transaction PCRX Common Stock Options Exercise $207,551 +18,834 +14% $11.02 158,171 28 Feb 2022 Direct
transaction PCRX Common Stock Sale $1,914,078 -28,641 -18% $66.83 129,530 28 Feb 2022 Direct F1
transaction PCRX Common Stock Options Exercise $2,127 +193 +0.15% $11.02 129,723 01 Mar 2022 Direct
transaction PCRX Common Stock Options Exercise $12,849 +1,166 +0.9% $11.02 130,889 01 Mar 2022 Direct
transaction PCRX Common Stock Sale $92,072 -1,359 -1% $67.75 129,530 01 Mar 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -9,807 -98% $0.000000 193 28 Feb 2022 Common Stock 9,807 $11.02 Direct F2
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -18,834 -94% $0.000000 1,166 28 Feb 2022 Common Stock 18,834 $11.02 Direct F3
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -193 -100% $0.000000* 0 01 Mar 2022 Common Stock 193 $11.02 Direct F2
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -1,166 -100% $0.000000* 0 01 Mar 2022 Common Stock 1,166 $11.02 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 he price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.750 to $67.155, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on May 3, 2012.
F3 The option vested and became exercisable as to 25% of the option shares on April 3, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.